Metformin has been the first-line drug for the treatment of type II diabetes mellitus for
decades, being presently the most widely prescribed antihyperglycemic drug. Retrospective …

Breast cancer is the most prevalent cancer and the leading cause of cancer-related death
among women worldwide. Type 2 diabetes–associated metabolic traits such as …

Two important, related pathways are involved in cancer growth: the insulin/insulin-like
growth factor-1 (IGF1) signaling pathway, which is activated when nutrients are available …

Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-
cancer agents individually or in combination with, frequently used, chemotherapeutic agents …

Due to the strong association between diabetes and cancer incidents, several anti-diabetic
drugs, including metformin, have been examined for their anticancer activity. Metformin is a …

Metformin is an orally available, biguanide derivative that is widely used in the treatment of
Type 2 diabetes. Recent preclinical data have demonstrated that it can also act as an …

Breast cancer is one of the most common malignancies in females. It is an etiologically
complex disease driven by a multitude of cellular pathways. The proliferation and spread of …

Metformin is widely used in the treatment of diabetes mellitus type 2 where it reduces insulin
resistance and diabetes-related morbidity and mortality. Population-based studies show that …

There is increasing interest in metformin's effects on the development, treatment, and/or
progression of breast cancer. This emerges from observational studies that diabetic women …

Metformin, a diabetes drug with well-established side effect and safety profiles, has been
widely studied for its anti-tumor activities in a number of cancers, including breast cancer …